who demonstrated a significant increase in the circulating M-MDSC (CD14+CD33+HLA-DR−/low) of newly diagnosed and relapsed DLBCL patients and found that the level of M-MDSC could be used as a biomarker for poor prognosis of DLBCL patients (34). Here, CD33 is linked to diffuse large B-cell lymphoma.